Related by context. All words. (Click for frequent words.) 77 MAGE A3 ASCI 75 cediranib 74 oral prodrug 74 CIMZIA TM certolizumab pegol 74 erythropoietic 74 STRIDE PD 74 relapsed MM 74 MGd 74 Traficet EN 74 NATRECOR ® 74 CIMZIA ™ 74 HuMax EGFr 73 elacytarabine 73 phase Ib 73 teriflunomide 73 recurrent glioblastoma multiforme 73 RSD# oral 73 Golimumab 73 receptor tyrosine kinase inhibitor 73 visilizumab 73 PROCHYMAL 73 GRNCM1 73 alvespimycin 73 canagliflozin 73 galiximab 73 SNT MC# 73 Afatinib 73 phase IIb clinical 73 fosbretabulin 73 intravenous cyclophosphamide 73 HuLuc# 73 canakinumab 72 brivaracetam 72 vidofludimus 72 YONDELIS 72 oral rivaroxaban 72 OHR/AVR# 72 CBLC# 72 Teriflunomide 72 CIMZIA TM 72 novel VDA molecule 72 CTAP# Capsules 72 flavopiridol 72 oral FTY# 72 velafermin 72 HIV HCV coinfected 72 IMA# 72 APTIVUS 72 elotuzumab 72 Mipomersen 72 pharmacokinetic interactions 72 GAMMAGARD 72 forodesine 72 chronic thromboembolic pulmonary 72 Tyrima 72 favorable pharmacokinetic profile 72 dose escalation phase 72 TACI Ig 72 Dasatinib 72 NP2 Enkephalin 72 GSK# [001] 72 mertansine 72 ZOLINZA 72 ELACYT 72 relapsing remitting MS RRMS 72 weekly subcutaneous injections 72 tocilizumab 72 BrachySil TM 72 phase IIa 72 metaglidasen 71 Methylnaltrexone 71 ENMD # 71 deferiprone 71 either acutely decompensated 71 posaconazole 71 antitumor effect 71 TRO# 71 eltrombopag 71 vismodegib 71 MYDICAR ® 71 sitaxsentan 71 eosinophilic asthma 71 Aviptadil 71 Azedra 71 HQK 71 VA# [002] 71 Zemplar Capsules 71 pomalidomide 71 CYT# potent vascular disrupting 71 Ophena TM 71 ACTEMRA TM 71 Safinamide 71 recurrent glioma 71 Pagoclone 71 lomitapide 71 cannabinor 71 renal toxicity 71 pharmacodynamic effects 71 TBC# 71 evaluating tivozanib 71 Xanafide 71 tarenflurbil 71 noninfectious uveitis 71 Aliskiren 71 oral methylnaltrexone 71 invasive candidiasis 71 bezafibrate 71 Tolvaptan 71 samalizumab 71 phase IIa clinical 71 placebo controlled clinical 71 HCV RESPOND 2 71 Aplidin 71 hyperphenylalaninemia HPA due 71 lumiliximab 71 olaparib 71 CINQUIL 71 somatostatin analog 71 olmesartan 71 Vidaza azacitidine 71 tolvaptan 71 rFVIIa 71 mycophenolate mofetil 71 solithromycin 71 Enzastaurin 71 multicenter Phase II 71 selective modulator 71 Ataluren 71 TNF antagonist 71 CA4P 70 Dapagliflozin 70 CYT# QbG# 70 TriRima 70 torezolid phosphate 70 Alequel 70 antiangiogenic therapy 70 pharmacodynamic properties 70 docetaxel Taxotere ® 70 Tarceva TM 70 Phase 1a clinical 70 Phase Ib clinical 70 Acute Ischemic Stroke 70 phase IIb trial 70 myopathy rhabdomyolysis 70 clevidipine 70 ganetespib 70 AZILECT ® 70 ADAGIO study 70 probiotic supplementation 70 Cloretazine 70 Vernakalant 70 ADVANCE PD 70 DU #b 70 Telintra 70 eprotirome 70 tipifarnib 70 cMET 70 mapatumumab 70 phase IIb study 70 DFMO 70 BAY #-# 70 sorafenib Nexavar 70 Aflibercept 70 Aclidinium 70 efalizumab 70 viral kinetics 70 gemifloxacin 70 blinded randomized placebo controlled 70 refractory gout 70 ZD# [001] 70 Octreolin 70 aldosterone antagonists 70 kidney urologic 70 Trandolapril 70 RhuDex ® 70 ACZ# 70 antiarrhythmic 70 imatinib therapy 70 tanespimycin 70 PRT# 70 dexanabinol 70 ATACAND 70 Vidofludimus 70 TRV# [001] 70 PSMA ADC 70 paricalcitol 70 Noxafil 70 randomized multicenter trial 70 BRIM2 70 INSPIRE Trial Phase III 70 hereditary deficiency 70 demonstrated antitumor activity 70 Phase #b/#a 70 receptor inhibitor 70 EVIZON 70 anticancer activity 70 K ras mutations 70 cilengitide 70 axitinib 70 TLK# 70 active comparator 70 Dalbavancin 70 Hepatotoxicity 70 thorough QT 70 ToGA 70 apremilast 70 DACH platinum 70 #I TM# 70 Phase 2a trial 70 Symadex 70 bortezomib Velcade 70 EndoTAG TM -1 70 calcineurin inhibitors 70 thalidomide Thalomid 70 PLX cells 70 Virulizin ® 70 Ceflatonin 70 Elocalcitol 70 HCV SPRINT 69 edifoligide 69 JAK inhibitor 69 Arranon 69 OMNARIS HFA 69 AZILECT R 69 fibrotic disease 69 RRMS patients 69 antiangiogenic agent 69 enzastaurin 69 Phase #/#a 69 antiproliferative effects 69 BRIM3 69 Pemetrexed 69 AGILECT R 69 IRX 2 69 midstage clinical 69 Zoraxel 69 Fibrillex TM 69 NLX P# 69 HCV NS5B polymerase 69 β blockers 69 motesanib 69 diabetic neuropathic pain 69 vascular disrupting agent 69 APTIVUS r 69 SERCA2a 69 preclinically 69 Subgroup analysis 69 neratinib 69 trastuzumab Herceptin ® 69 RhuDex 69 Phase IIIb clinical 69 oral JAK1 69 PRTX 69 PROMACTA 69 Degarelix 69 urocortin 2 69 HGS ETR2 69 nephrotoxicity 69 gadobutrol 69 DDP# 69 Epratuzumab 69 anti leukemic 69 Inhaled nitric oxide 69 Darinaparsin 69 esophageal candidiasis 69 fenretinide 69 antidepressant efficacy 69 NMDA antagonists 69 antitumor efficacy 69 chronic myocardial ischemia 69 beta lactam antibiotic 69 varespladib 69 isavuconazole 69 factor Xa inhibitor 69 Diamyd r vaccine 69 Androxal TM 69 cardiac repolarization 69 Bezielle 69 Mycophenolate Mofetil 69 antiresorptive 69 mGluR5 NAM 69 Genz # 69 INCB# [003] 69 lenalidomide dexamethasone 69 poststroke depression 69 MGN# 69 hepatotoxic 69 regorafenib 69 intravenous bisphosphonates 69 CCX# 69 pharmacokinetic characteristics 69 adrenal suppression 69 Archexin 69 INVEGA ® 69 Tasimelteon 69 Muraglitazar 69 myeloproliferative diseases 69 atacicept 69 cardioprotective effects 69 Lu AA# 69 GLYX 69 mTOR inhibitors 69 diabetic kidney 69 VEGF inhibitors 69 Exherin TM 69 salmeterol fluticasone 69 tumor lysis syndrome 69 calcineurin inhibitor 69 NATRECOR R 69 iniparib 69 pertuzumab 69 ON #.Na 69 systemic hypotension 69 PEG SN# 69 selenium supplementation 69 Glypromate 69 randomized Phase IIb 69 myelofibrosis polycythemia vera 69 CEQ# 69 6R BH4 69 Hypotension 69 Lixivaptan 69 Thiovir 69 corticosteroid therapy 69 tipranavir 69 TOLAMBA 69 Arikace 69 CaPre TM 69 AVERROES 69 rtPA 69 gallium nitrate 69 budesonide foam 69 HeFH 69 H. pylori eradication 69 Phase IIA 69 antifibrotic 69 Plasmin 69 NV1FGF 69 EchoCRT 69 Dacogen injection 69 Dacogen decitabine 69 paclitaxel poliglumex 69 GALNS 69 GSK# [002] 69 Gleevec imatinib 69 ritonavir boosted 69 acetonide FA 69 intravascular hemolysis 69 inecalcitol 69 REMINYL ® 69 RoACTEMRA 69 Actimmune ® 69 pain palliation 69 INCB# [001] 69 Squalamine 69 Denufosol 69 anthracycline chemotherapy 69 reduce serum phosphate 69 AA Amyloidosis 69 severe hypercholesterolemia 68 placebo controlled studies 68 pharmacokinetic PK study 68 sorafenib tablets 68 nab paclitaxel 68 PRIMO CABG 68 OvaRex ® MAb 68 pharmacodynamic PD 68 intravenous iv 68 imatinib resistance 68 KRAS status 68 Gleevec resistant 68 rEV# 68 Tasigna prolongs 68 tigecycline 68 Vandetanib 68 PXD# 68 NVA# 68 Hydroxyurea 68 recombinant tissue plasminogen 68 ara C 68 pivotal bioequivalence 68 ularitide 68 QTc prolongation 68 pulmonary hypertension PH 68 HIF PHI 68 CTEPH 68 invasive aspergillosis 68 superficial bladder cancer 68 AEG# 68 ProSavin 68 serum phosphate levels 68 antitumor effects 68 opioid induced bowel dysfunction 68 TPI ASM8 68 ximelagatran 68 SYMMETRY trial 68 interferon gamma 1b 68 glatiramer 68 Non inferiority 68 VADT 68 ocrelizumab 68 macrolide antibiotic 68 R#/MEM # 68 ALB # 68 SNT-MC#/idebenone 68 plasma kallikrein inhibitor 68 HCV protease inhibitors 68 Rezular 68 plasma pharmacokinetics 68 preclinical efficacy 68 antiangiogenic agents 68 oral antiviral 68 metastatic neuroendocrine tumors 68 ataluren 68 QLT# 68 alkylating agent 68 pentoxifylline 68 PAOD 68 MULTAQ 68 Pseudomonas aeruginosa infections 68 dexpramipexole 68 Phase Ib study 68 Torisel 68 allogeneic HSCT 68 Kinoid 68 Lofexidine 68 efficacy tolerability 68 Plicera 68 TNF alpha inhibitor 68 reslizumab 68 Natalizumab 68 HIF PH inhibitors 68 dosing cohort 68 Lacosamide 68 oxymorphone ER 68 BAL# [002] 68 intensive lipid lowering 68 protease inhibitor PI 68 Avanafil 68 ziconotide 68 BEXXAR Therapeutic Regimen 68 MYDICAR 68 TTF Therapy 68 BMS# 68 immunomodulatory therapy 68 clazosentan 68 Onrigin 68 GW# [003] 68 Pimavanserin 68 alefacept 68 Granulocyte Colony Stimulating Factor 68 ipratropium bromide 68 Deforolimus 68 KRN# 68 aspirin clopidogrel 68 nonrandomized 68 XmAb# 68 CAMMS# 68 dosage regimens 68 Pirfenidone 68 adipiplon 68 thetreatment 68 mTOR inhibition 68 estramustine 68 acute mania 68 Certolizumab pegol 68 PROactive study 68 avosentan 68 clomipramine 68 MYCAMINE 68 coadministration 68 aripiprazole Abilify 68 liposomal amphotericin B 68 Bucindolol 68 Prodarsan 68 nitrofurantoin 68 lung fibrosis 68 rt PA 68 EOquin TM 68 DEB# 68 generation purine nucleoside 68 PRADAXA 68 AGHD 68 Ocrelizumab 68 ExTRACT TIMI 68 PREZISTA r 68 KAPIDEX 68 lipid lowering therapies 68 Perforomist ™ Inhalation Solution 68 Vimpat R 68 topical calcineurin inhibitors 68 phase IIb III 68 icatibant 68 pediatric malignancies 68 Sapacitabine 68 LymphoStat B belimumab 68 ORMD 68 neurotrophic 68 CANCIDAS 68 Pafuramidine 68 Phase Ib II 68 G#DT 68 erlotinib Tarceva ® 68 Altastaph 68 Cardiotoxicity 68 psoriatic arthritis PsA 68 bronchodilatory 68 antiviral efficacy 68 metastatic HRPC 68 Phase IIB 68 mGluR2 NAM 68 fluvastatin 68 pharmacodynamic parameters 68 ruxolitinib 68 EDEMA3 trial 68 ISTODAX 68 endothelin antagonists 68 perampanel 68 palifermin 68 SUTENT ® 68 Rheos System 68 CARE HF 68 basal bolus regimen 68 pharmacokinetic PK 68 Val HeFT 68 SERMs 68 irbesartan 68 ATL/TV# 68 ORENCIA ® 68 RSD# 68 Pyridorin 68 UPLYSO 68 guanfacine extended release 68 Pazopanib 68 maximally tolerated dose 68 hepatic toxicity 68 atrasentan 68 favorable tolerability 68 MMP inhibitors 68 inhibitor RG# 68 MADIT II 68 SCIg 68 tolerability profiles 68 OncoVex 68 JAK Inhibitor 68 TG# [003] 68 iroxanadine 68 noscapine 68 SinuNase TM 68 subcutaneous PRO 68 trastuzumab DM1 68 benign prostatic hypertrophy BPH 68 RLY# 68 Diabetic Macular Edema 68 immunomodulatory agents 68 VP# [004] 68 Vitaxin 68 antithrombotic therapy 68 inhaled iloprost 68 Darusentan 68 MERLIN TIMI 68 efaproxiral 68 Pertuzumab 68 MEVACOR 68 tegaserod 68 BETAS 68 antiepileptics 68 PNH patients 68 aldosterone antagonist 68 virological response 68 zoledronate 68 antioxidant supplementation 68 Xelox 68 Candesartan 68 CVBT #H 68 renoprotective 68 Ranolazine 68 azacytidine 68 acyclovir Lauriad R 68 CALGB # [002] 68 COREG 68 CG# [003] 68 DAPT 68 SPIRIVA HandiHaler 68 PhG alpha 1 68 Catena ® 68 uric acid lowering 68 Vascugel 68 DermaVir Patch 68 methylnaltrexone 68 Nexavar sorafenib 68 Linagliptin 68 Intervention Effectiveness 68 cytopenias 68 Phenoptin 68 MEND CABG 68 TMC# C# 68 intravenous immunoglobulin IVIg 68 gastrointestinal stromal tumors GIST 68 CLARITY study 68 cobiprostone 68 azilsartan medoxomil 68 Serdolect ® 68 therapeutic regimens 68 proteasome inhibitor 68 severe gastroparesis 68 antidiabetic drugs 68 LibiGel ® 68 Ozarelix 68 Fondaparinux 68 Amplimexon 68 SCH # 68 Forodesine HCl 68 #D#C# 68 prostate carcinogenesis 68 dose proportionality 68 IL# PE#QQR 68 CINTREDEKIN BESUDOTOX 67 anti androgen 67 interleukin IL -# 67 anti arrhythmic drug 67 refractory CLL 67 catheter occlusion 67 sargramostim 67 adalimumab Humira 67 oral Xeloda 67 platelet inhibitor 67 radezolid 67 Valdoxan 67 LUX Lung 67 pyridostigmine 67 BrachySil 67 CYP #A# 67 rosuvastatin #mg 67 rALLy clinical trial 67 hepatotoxicity 67 complete cytogenetic response 67 pan HDAC inhibitor 67 analgesic efficacy 67 chemopreventive agent 67 histone deacetylase inhibitor 67 GFT# 67 LY# [003] 67 pouchitis 67 Hsp# Inhibitor 67 evaluating CK # 67 hyperoxaluria 67 Cleviprex TM clevidipine 67 Cimzia TM 67 trodusquemine 67 hypercholesterolemic patients 67 Triapine R 67 direct thrombin inhibitors 67 LHRH antagonists 67 amrubicin 67 TNF alpha antagonist 67 antiplatelet agent 67 GOUT 67 delafloxacin 67 cilostazol 67 NAbs 67 Sym# 67 acadesine 67 refractory acute myeloid 67 antiplatelet therapies 67 bovine thrombin 67 pharmacodynamic profile 67 vasodilators 67 Egrifta 67 CYP#A# inhibitors 67 Amphinex ® 67 multicenter Phase III 67 lenalidomide Revlimid R 67 immunological responses 67 dyslipidaemia 67 rilonacept 67 Microplasmin 67 investigational monoclonal antibody 67 Carvedilol 67 guanfacine 67 Varespladib 67 imexon 67 intravenous dosing 67 neuropsychiatric symptoms 67 CHAMPION PCI 67 heavily pretreated 67 HMG CoA reductase inhibitors 67 dose escalation clinical 67 pheochromocytoma 67 BoNTA 67 Prostate AdenoCarcinoma Treatment 67 Nesiritide 67 phase IIIb 67 cytostatic 67 Tekamlo 67 alvimopan 67 Lenocta 67 serum phosphorous 67 acute humoral rejection 67 TORISEL 67 mildly symptomatic 67 C1 INH deficiency 67 Triolex 67 vaso occlusive crisis 67 cardiac toxicity 67 Bicifadine 67 PD LID 67 DXL# 67 Factor VIIa 67 VAPRISOL 67 rALLy 67 diabetic gastroparesis 67 tesofensine 67 ADP receptor antagonist 67 virus HCV protease inhibitor 67 Refractory Angina 67 corticosteroid dexamethasone 67 adecatumumab 67 Lp PLA 2 67 romidepsin 67 TELINTRA 67 candesartan cilexetil 67 refractory chronic lymphocytic 67 Fingolimod 67 hour bronchodilation 67 bazedoxifene conjugated estrogens 67 malignant ascites 67 phase 2a 67 fosamprenavir 67 bendamustine 67 JAK2 inhibitor 67 Stedivaze 67 eculizumab therapy 67 nucleoside analog 67 argatroban 67 APTIVUS ritonavir 67 ganaxolone 67 SAR# [004] 67 tolevamer 67 torezolid 67 Bosentan 67 genotypic resistance 67 anticlotting drugs 67 KIACTA ™ 67 CLORETAZINE TM VNP#M 67 BENICAR HCT 67 CIPN 67 florbetaben 67 Amrubicin 67 aflibercept VEGF Trap 67 idarubicin 67 cerebral vasospasm 67 ONCONASE R 67 omega interferon 67 clobazam 67 ruboxistaurin 67 IFN α 67 orally administered inhibitor 67 5alpha reductase 67 Oral NKTR 67 metastatic RCC 67 PSN# [002] 67 bevacizumab Avastin 67 Lisofylline 67 nucleotide analogue 67 ORENCIA R 67 dacetuzumab 67 aleglitazar 67 ImmunoVEX HSV2 67 anti amnesic 67 antiarrhythmic drugs 67 Meets Primary Endpoint 67 BNC# 67 basiliximab 67 OncoVEX GM CSF 67 EP #R 67 immunomodulation 67 S/GSK# 67 ticagrelor Brilinta 67 systemically administered 67 herpetic keratitis 67 EDARBI 67 RezularTM 67 dual endothelin receptor antagonist 67 glatiramer acetate 67 PNP inhibitor 67 Abatacept 67 LAF# 67 ß blockers 67 indibulin 67 tremelimumab 67 ATL# [001] 67 tramiprosate Alzhemed TM 67 urate lowering 67 GRN# 67 somatostatin analogues 67 HuMax CD4 67 masitinib 67 TYGACIL 67 Panzem 67 midstage trials 67 AVOREN 67 relapsed ovarian cancer 67 hematological parameters 67 pharmacokinetics pharmacodynamics 67 immune modulatory 67 TransVax ™ 67 lanreotide 67 antiarrhythmic drug 67 Hepatocellular Carcinoma HCC 67 TYSABRI natalizumab 67 ACV1 67 Lisofylline LSF 67 Carfilzomib 67 nalbuphine ER 67 QVA# 67 reboxetine 67 Oral corticosteroids 67 thyrotropin 67 Etanercept 67 Teriparatide 67 liposomal formulation 67 Tocosol Paclitaxel 67 haematologic 67 AZILECT 67 Atrasentan 67 antiangiogenic 67 ibandronate 67 urothelial cancer 67 dexamethasone Decadron 67 cardiovascular calcification 67 iclaprim 67 darbepoetin alpha 67 standard chemotherapy regimen 67 EXJADE 67 lowering triglyceride levels 67 Gefitinib 67 iloprost 67 Onbrez Breezhaler 67 sunitinib malate 67 briakinumab 67 Eculizumab 67 Exforge HCT 67 COPAXONE R 67 PEGylated interferon beta 1a 67 Cimzia ® certolizumab pegol 67 Randomized Double blind 67 antineoplastic 67 Dose escalation 67 BRAF inhibitor 67 hematological toxicity 67 crizotinib PF # 67 Leber Hereditary Optic Neuropathy 67 Eltrombopag 67 lapatinib Tykerb 67 prucalopride 67 Temsirolimus 67 Romidepsin 67 multicenter trials 67 Deferiprone 67 orBec 67 tafamidis 67 Poly ICLC 67 colesevelam HCl 67 Phase IIb III 67 Valortim ® 67 Pivotal Phase III 67 torsade de pointes 67 Saforis 67 Zalypsis 67 Romiplostim 67 busulfan 67 taxane resistant 67 pharmacodynamic endpoints 67 ascending dose 67 lupus nephritis 67 DCCR 67 recurrent glioblastoma 67 albiglutide 67 miconazole Lauriad ® 67 SRT# [003] 67 ARIKACE 67 overlapping toxicities 67 hepatic fibrosis 67 Rilonacept 67 Trofex 67 Onconase 67 NeuroVax 67 PROVENGE sipuleucel T 67 HyQ 67 biliary tract cancer 67 EGFR TKI 67 anti angiogenic agents 67 AST ALT 67 steroid dexamethasone 67 LHRH agonists 67 phase Ib clinical 67 parkinsonian symptoms 67 pharmacokinetic equivalence 67 diarrhea predominant irritable 67 Apoptone 67 hypercholesterolaemia 67 EXPLORE Xa 67 HER2 overexpression 67 MYLOTARG 67 bardoxolone methyl 67 Cinquil 67 treprostinil 67 CA9 SCAN 67 selegiline 67 neovascular 67 double blinded placebo 67 secretin 67 SPRYCEL ® 67 statins cholesterol lowering 67 immune modulator 67 Rasilez Tekturna 67 REP# 67 rhITF 67 Silodosin 66 retinal vein occlusion 66 GnRH agonists 66 unresectable tumors 66 Dyloject TM 66 bicifadine 66 endometrial hyperplasia 66 Lubiprostone 66 Interferon alpha 66 MVax 66 weekly intravenous infusions 66 ACAPODENE 66 ASCEND HF 66 KETEK 66 synthetic retinoid 66 huC# DM4 66 angiogenesis inhibitor 66 cinacalcet 66 Inhaled AAT 66 Nebulized 66 Vorinostat 66 safinamide 66 metreleptin 66 MP4OX 66 reactogenicity 66 relapsed ALL 66 immunopathology 66 sunitinib Sutent 66 ACCORD Lipid 66 multitargeted 66 multicenter randomized placebo controlled 66 Aggrastat ® tirofiban hydrochloride 66 gemcitabine Gemzar ® 66 candidemia 66 Roflumilast 66 CRLX# 66 Phase IIIb study 66 antithrombotic 66 platelet inhibition 66 atherogenic dyslipidemia 66 baminercept 66 Proellex TM 66 infliximab Remicade 66 OMP #R# 66 edoxaban 66 myoblast therapy 66 Fulvestrant 66 rosuvastatin Crestor 66 lacosamide 66 APOPTONE 66 esomeprazole Nexium 66 arterial thrombosis 66 postoperative chemotherapy 66 immune reconstitution 66 INTEGRILIN R 66 cisplatin gemcitabine 66 Primary endpoints 66 vemurafenib 66 ALA PDT 66 teduglutide 66 radiolabeled TM# 66 LEUKINE 66 Subgroup analyzes 66 decitabine 66 ACOMPLIA R 66 APTIVUS R 66 mRCC 66 tolerability pharmacokinetics 66 Phase #b/#a trial 66 DASISION 66 arbaclofen 66 relapsed MCL 66 ROTARIX 66 Akt activation 66 adrenocortical cancer 66 PROSTVAC TM 66 RAPAFLO R 66 triphendiol 66 EGFR HER2 66 IFN beta